Clinical experiences with G17DT in gastrointestinal malignancies

Expert Review of Anticancer Therapy
Aiwu R He, John L Marshall

Abstract

The development of new agents for the treatment of gastrointestinal malignancies is increasing in pace and importance. The discovery of novel targets, namely the epidermal growth factor receptor and vascular endothelial growth factor, have sparked an explosion of new agents being tested in gastrointestinal malignancies. Clearly, novel agents and approaches are required. G17DT is a novel immunoconjugate designed to elicit a humoral response against the N-terminal end of G17 gastrin. In this overview, the authors summarize the clinical research focused on gastrointestinal tract cancers to date. In total, there is a clear signal of efficacy with this compound, although further testing is required in order for this efficacy to be demonstrated in a manner that will support regulatory approval.

References

Apr 1, 1989·British Journal of Cancer·S WatsonD Morris
Jul 15, 1982·International Journal of Cancer. Journal International Du Cancer·O KoboriF Martin
Jul 15, 1994·Science·C SevaT Yamada
Dec 2, 1993·International Journal of Cancer. Journal International Du Cancer·P PisaniJ Ferlay
Oct 15, 1996·The Journal of Clinical Investigation·T C WangG J Dockray
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·S A WatsonJ D Hardcastle
Apr 3, 1999·International Journal of Cancer. Journal International Du Cancer·S A WatsonJ D Hardcastle
Dec 1, 2001·Expert Opinion on Biological Therapy·S A Watson, A D Gilliam
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B T BrettM E Caplin
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P DiamandisDionyssios Katsaros
Feb 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salah-Eddin Al-BatranElke Jaeger
May 12, 2004·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A D GilliamD Michaeli
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry Q XiongJames L Abbruzzese
Jul 29, 2004·Current Pharmaceutical Design·William Rengifo-Cam, Pomila Singh
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetUNKNOWN GISCAD
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L Shapiro

❮ Previous
Next ❯

Citations

May 19, 2011·Cancer Immunology, Immunotherapy : CII·Chiara TieppoFabio Farinati
Dec 20, 2008·Expert Review of Vaccines·Philippe Fournier, Volker Schirrmacher
Jan 15, 2013·Journal of Drug Targeting·Jie SongZengshan Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
A D GilliamDov Michaeli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
B T BrettM E Caplin
© 2022 Meta ULC. All rights reserved